by Elena Iemma | May 28, 2025 | Blog, Uncategorized
The new CSO starts on June 1st! Drumroll please…. We are pleased to welcome Dr. Vibha Jawa as the new Chief Scientific Officer at EpiVax! Please see this link for more information about this latest update to EpiVax 2.0. (I will be around to help transition)....
by Elena Iemma | May 19, 2025 | Blog
FDA Roadmap to Reducing Animal Testing:A Step Toward Smarter Tools for in silico Immunogenicity Risk Assessment The FDA’s new Roadmap to Reducing Animal Testing in Preclinical Safety Studies lays out a phased plan to move away from animal models and toward...
by Elena Iemma | Apr 30, 2025 | Blog
Is “Artificial” Intelligence an Option for your ADA? In Case You Missed It: Better ADA Prediction! Guilhem Richard, our CTO, recently presented our new ADA (anti-drug antibody) prediction model to the Antibody Society. The accuracy of the model improved...
by Elena Iemma | Apr 1, 2025 | Blog
March of the Teenage B Cells BCR are Like Teenagers I remember teenagers. I suppose that the last phase of teen development prepares you for their departure, and then they are gone… Hopefully, the memories of their sweet, former personalities will last longer than the...
by Elena Iemma | Mar 1, 2025 | Blog
The EpiVax team is dedicated to advancing the science of immunogenicity assessment and streamlining the preclinical drug development process for our partners worldwide. This month, we’re excited to share several updates with you, including new and updated in silico...
by Elena Iemma | Feb 24, 2025 | Blog
We know, and We Care There is not a lot of room in the TOL (Thinking out Loud) Newsletter to share our feelings about the news in the USA, but we want you to know that we ARE aware, and we REALLY CARE about the negative impact of recent...
